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Abstract
Background: Processes of restenosis, following arterial
injury, are complex involving different cell types pro-
ducing various cytokines and enzymes. among those
enzymes, smooth muscle cell-derived matrix metallo-
proteinases (MMPs) are thought to take part in cell
migration,  degrading  of  extracellular  matrix,  and
neointima  formation.  MMP-9,  also  known  as  gelati-
nase B, is expressed immediately after vascular injury
and  its  expression  and  activity  can  be  inhibited  by
statins. using an established in vivo model of vascular
injury, we investigated the effect of the HMG-coa re-
ductase inhibitor rosuvastatin on MMP-9 expression
and neointima formation.
Materials  and  Methods: 14-week  old  male  sprague
dawley rats underwent balloon injury of the common
carotid artery. Half of the animals received rosuvas-
tatin (20 mg/kg body weight/day) via oral gavage, be-
ginning 3 days prior to injury. Gelatinase activity and
neointima formation were analyzed 3 days and 14 days
after balloon injury, respectively. 14 days after vascular
injury,  proliferative  activity  was  assessed  by  staining
for Ki67.
Results:  after  14  days,  animals  in  the  rosuvastatin
group showed a decrease in total neointima formation
(0.194 ﾱ 0.01 mm2 versus 0.124 ﾱ 0.02 mm2, p<0.05)
as well as a reduced intima/media ratio (1.26 ﾱ 0.1
versus 0.75 ﾱ 0.09, p<0.05). Balloon injury resulted in
increased activity of MMP-9 3 days after intervention
for  both  rosuvastatin  treated  animals  and  controls
with  no  significant  difference  observed  between  the
groups. there was a trend towards a reduction in the
number of Ki67-positive cells 14 days after injury.
Conclusions: Rosuvastatin attenuates neointima forma-
tion  without  affecting  early  MMP-9  activity  in  a  rat
model of vascular injury.
IntRoductIon
arterial  restenosis  following  balloon  angioplasty  re-
mains  a  common  clinical  limitation  even  after  stent
implantation [1]. this effect is mainly caused by accel-
erated neointima formation due to smooth muscle cell
migration and proliferation after endothelial damage
[2]. several pathophysiological mechanisms have been
discussed.  some  studies  suggest  profuse  vascular
wound  healing  due  to  adjacent  endothelial  cells  and
endothelial  progenitors  [3,  4].  others  have  demon-
strated  a  tGF-b-dependent  mechanism  of  constric-
tive  arterial  remodeling  and  formation  of  intimal
thickening composed of smooth muscle cells [5]. In
part, vascular remodeling is also induced by the release
of  sMc  matrix  degrading  enzymes,  such  as  matrix
metalloproteinases and the tissue inhibitors of matrix
metalloproteinases (tIMP) [6, 7]. In particular, MMP-
9 is upregulated following vessel injury [8]. Inhibition
of MMPs resulted in  reduced sMc proliferation and
inhibition of neointimal hyperplasia [9, 10]. since it is
known  that  hydroxymethylglutaryl  coenzyme  a
(HMG-coa) reductase inhibitors are beneficial in pri-
mary and secondary prevention of cardiovascular dis-
ease, and that their pleiotropic effects are independent
of their lipid-lowering potential, some studies have fo-
cused on the effect of statin therapy on prevention of
restenosis [11-17]. several in vitro and in vivo studies
demonstrated reduction of MMP-9 expression follow-
ing statin treatment [19, 20].
Recently, it has been demonstrated that the potent
HMG-coa  reductase  inhibitor  rosuvastatin  reduces
neointima formation in a hypertensive rat model [16].
Furthermore rosuvastatin promotes bone-marrow de-
pendent  re-endothelialization  and  reduces  neointima
formation in mice [21].
our study evaluated the effect of rosuvastatin on
MMP-9 expression and neointima formation in a rat
model of vascular injury.
MatERIals and MEtHods
anIMals and dRuG tREatMEnt
twenty two male sprague dawley rats (380 – 420g;
charles River laboratories, sulzfeld, Germany) at the
age of 14 weeks were kept within the animal care fa-
cility  of  the  university  of  Heidelberg.  animals  re-
ceived free water and food (standard chow diet) ad li-
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hour light/dark cycle. animals were randomly divided
into rosuvastatin treated group and controls. starting
three  days  prior  to  balloon  injury,  half  the  rats  re-
ceived rosuvastatin (20mg/kg bodyweight / day) via
oral gavage. a number of the rats were euthanized 3
days after balloon injury for immunoblot and gelati-
nolytic assay. For the evaluation of neointima forma-
tion, additional rats were euthanized 14 days after in-
jury.  Housing  and  care  of  animals,  and  procedures
carried  out  in  this  study  were  performed  in  accor-
dance with the guidelines and regulations composed
by the animal care committee of the university of
Heidelberg.
Balloon InJuRy
Rats were anesthetized by intraperitoneal injection of
ketamine  (100mg/kg  body  weight)  and  xylazine
(15mg/kg bodyweight). after midline incision of the
neck, the left external carotid artery was exposed and a
2F  balloon  catheter  (Baxter  Healthcare)  was  intro-
duced up to the aortic outlet of the common carotid
artery. the balloon was then inflated with saline solu-
tion until a slight resistance was felt. While rotating,
the  balloon  was  pulled  back  through  the  common
carotid artery to denude the endothelium. this proce-
dure was repeated twice. afterwards, the catheter was
removed,  the  external  carotid  artery  ligated  and  the
wound was closed. contralateral right arteries served
as uninjured controls. three and 14 days after surgery
rats were anaesthetized as described previously, blood
was collected from the inferior vena cava, stored for
further  use,  and  animals  were  euthanized  by  exsan-
guination. Rats were perfused with 20 ml phosphate-
buffered saline solution at physiological pressure via
left ventricle. left and right common carotid arteries
were excised, adhering connective tissue was removed
and stored at -80ﾰc.
dEtERMInatIon oF PlasMa lIPId lEvEls
total  serum  cholesterol,  high-density  lipoprotein
(Hdl) and low-density lipoprotein (ldl) cholesterol
were determined enzymatically in heparinized plasma.
MoRPHoMEtRIc analysIs oF nEoIntIMa
FoRMatIon/IMMunoHIstocHEMIstRy
common  carotid  arteries  were  serially  sectioned  (5
ﾵm)  and  stained  with  hematoxylin-eosin  (HE).  sec-
tions  were  evaluated  blind  using  computer-assisted
morphometry  (olympus  Mikroskopie  Hamburg, 
Germany  and  Image  Pro,  Media  cybernetics,  silver
spring, usa). the size of the neo-intimal layer was
determined as the area between internal elastic lamina
and  the  luminal  circumference  (data  expressed  in
mm2).  Furthermore,  the  total  number  of  cells  was
evaluated  by  counting  nuclei.  In  addition,  neo-
intima/media ratios were calculated by a blinded ob-
server. 
to determine proliferation and endothelial integrity,
serial  sections  were  stained  for  Ki67  with  a  rabbit
polyclonal antibody (abcam, cambridge, uK), a rabbit
von Willebrand factor antibody (dako, carinteria, ca,
usa) and a directly FItc conjugated a-smooth mus-
cle actin antibody (sigma-aldrich, st. luis Mo, usa).
Proliferation index was calculated as number of Ki67-
positive cells / total amount of cells.
PRotEIn ExtRactIon FoR WEstERn Blot and
GElatInolytIc assay
For gelatinolytic assay, frozen arteries were homoge-
nized with lysis buffer (50 mmol/l tris-Hcl, pH 7,6;
150  mmol/l  nacl;  5  mmol/l  cacl2;  0,05%  Brij-35;
0,02% nan3; 1% triton x-100). lysates were sheared
by  ultrasonic  disruption,  and  centrifuged  at  14.000
r.p.m at 4ﾰc for 10 min. supernatants were used as
whole cell lysates and protein concentration was deter-
mined  using  the  Bradford  method  (Bio-Rad  Protein
assay). 
GElatInolytIc assay
ten  ﾵg  protein  were  used  to  analyze  vessel  tissue
gelatinase activity. Gelatinase activity was detected in a
10%  gelatine  gel  (Invitrogen,  carlsbad,  usa)  using
sds running buffer (all chemicals Invitrogen, carls-
bad, usa). after electrophoresis, gels were incubated
with zymogram renaturing buffer for 30 min and de-
veloped in zymogram developing buffer for 12 hours.
Gels were stained with 0.125% coomassie blue R-250
for 30 min in 10% acetic acid and 50% methanol. Fi-
nally, gels were destained with a solution containing
10% acetic acid and 10% methanol until clear bands of
gelatinolysis appeared on a dark blue background. the
molecular weight of the gelatinolytic bands was esti-
mated  by  comparison  with  prestained  molecular
weight  markers  (Bio-Rad,  Munich,  Germany).  Gels
were dried and scanned by densitometry.
WEstERn BlottInG
ten ﾵg of protein were seperated by 10% sds-PaGE
Gel (Invitrogen, carlsbad, usa) and transferred to ni-
trocellulose membranes (schleicher und schuell, Ger-
many).  after  blocking  (5%  nonfat  milk  powder  dis-
solved  in  tBst)  the  membrane  was  incubated  with
primary antibody (polyclonal goat anti rat MMP-9, di-
lution 1:2000) overnight at 4ﾰc, washed three times
with tBst, followed by incubation with a secondary
antibody for 1 hour at room temperature. after wash-
ing,  bands  were  visualized  with  Ecl  (amersham
Biosience, usa), recorded on hyperfilm (amersham)
and quantified by densitometry (Bio-Rad). antibodies,
used in this study, were purchased from santa cruz
Biotechnology, santa cruz, usa. 
statIstIcal analysIs
all data were expressed as mean ﾱ sEM or as mean 
ﾱ  sd,  as  indicated.  significant  differences  between
means in plasma lipid profiles were determined with
the  two-tailed  unpaired  student`s  t-test,  differences 
in  neointima  size  using  the  Mann-Whitney  u-test. 
a  p-value  <0.05  was  considered  statistically  signifi-
cant.
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EFFEct on PlasMa lIPId lEvEls
at the time of euthanasia, animals showed no signifi-
cant differences in total cholesterol, Hdl and ldl
cholesterol. Furthermore, there were no differences in
bodyweight (table 1).
MoRPHoMEtRIcal analysIs
compared to the controls, treatment with rosuvastatin
lead  to  a  decrease  of  neointima  area  (0.194  ﾱ  0.01
mm2 versus  0.124  ﾱ  0.02  mm2,  p<0.05)  and
intima/media  ratio  (1.26  ﾱ  0.1  versus  0.75  ﾱ  0.09,
p<0.05) 14 days after injury (Fig. 1). total number of
cell nuclei within the neointima was also significantly
reduced in the arteries of rosuvastatin-treated rats, as
compared to control animals (3950 ﾱ 263 versus 5262
ﾱ 248, p<0.01). 
PRolIFERatIon/IntEGRIty oF EndotHElIal layER
Ki67  staining  was  used  to  determine  proliferation.
there was a trend towards a reduction in the number
of  Ki67-positive cells in rosuvastatin-treated animals
(2.1 ﾱ 0.17 versus 1.6 ﾱ 0.13; p = 0.058). However,
the  difference  did  not  reach  statistical  significance
(Fig. 2 aB).
two weeks after injury, arteries still showed incom-
plete  re-endothelialisation,  as  evaluated  by  staining
with  an  immunofluorescence-antibody  against  von
Willebrand factor and a-smooth muscle actin. no sig-
nificant  differences  between  treatment  groups  could
be detected (data not shown, Fig. 2 c).
GElatInolytIc actIvIty
Balloon injury of rat arteries upregulated expression
of a 92-kd band in the gelatin zymography 3 days af-
ter injury. no signal could be detected in the non-de-
nudated contralateral vessels (right cca), which sug-
gests that these 92-kd proteins are induced by injury.
this band corresponds to a form of rat 95-kd type
Iv collagenase/gelatinase (MMP-9) [21]. However no
difference  could  be  detected  between  rosuvastatin
treated and control rats (3754 ﾱ 1074 versus 3488 ﾱ
1816; Fig. 3a).
WEstERn BlottInG
MMP-9 protein expression in cca was determined by
Western blot in rosuvastatin treated rats and controls.
Balloon injury resulted in an induction of MMP-9 ex-
pression in arteries 3 days after de-endothelialization.
contralateral vessels in the same rats showed no in-
duction  of  MMP-9.  again,  there  was  no  significant
difference  between  rosuvastatin  treated  and  control
animals (Fig. 3B).
dIscussIon
Percutaneous coronary interventions (PcI) are widely
used for treatment of coronary heart disease. How  -
ever, long-term benefit is often limited by restenosis,
occurring  in  about  30%  of  patients  following  bare
metal  stent  implantation  [23].  Introduction  of  drug
eluting stents has decreased the incidence of resteno-
sis significantly but is associated with several problems
such as stent thrombosis [24].
Remodeling processes of the extracellular matrix by
MMPs  are  essential  for  neointima  formation  in
postangioplasty restenosis as well as in aortocoronary
vein graft vasculopathy [8, 25]. HMG-coa reductase
inhibitors  are  known  to  suppress  MMP-expression
and  are  therefore  a  potential  treatment  option  in
restenosis prevention [19, 20, 26].
using a standard animal model of vascular injury
we were able to demonstrate a significant reduction of
neointima formation in rats treated with rosuvastatin.
these data are in accordance with other studies in rats
and mice, whereas Kappert et al. (2006) only observed
an increase in luminal circumference but no difference
in total neointima size, nor in intima/media ratio [16,
17, 26]. Prevention of restenosis by HMG-coa reduc-
tase inhibitors might be dose-dependent. Kappert et
al.(2006)usedrosuvastatininadoseof only 1mg/kg/d
whereas  we  and  van  de  Harst  (2006)  administered 
rosuvastatin in a dose of 20 mg/kg/d, a dose previ-
ously demonstrated to inhibit hepatic HMG-coa re-
ductase by 90% in rats [16, 17, 18].
It has been demonstrated that vascular injury causes
early  upregulation  of  matrix  metalloproteinase-2
(MMP-2, gelatinase a) and matrixmetalloproteinase-9
(MMP-9, gelatinase B) and therefore might play an im-
portant role in sMc migration [8]. using balloon de-
endothelialization, an effective method for causing se-
vere vascular damage, we showed that gelatinase B ac-
tivity was upregulated 3 days after intervention. How-
ever, rosuvastatin treatment had no effect on expres-
sion or gelatinolytic activity of gelatinase B after bal-
loon injury. therefore, prevention of restenosis by ro-
suvastatin must act via an MMP-independent mecha-
nism. 
consistent with other studies, we found Ki67-posi-
tive cells within the neointima of all animals 14 days
after  injury.  there  was  a  trend  towards  reduced 
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Table 1. Body weight and lipid profile. no significant difference in levels of total cholesterol, Hdl and ldl as well as body
weight could be detected.
Body Weight total cholesterol ldl cholesterol Hdl cholesterol triglycerides
n (gram) (mg/dl) (mg/dl) (mg/dl) (mg/dl)
Rosuvastatin 10 416ﾱ23 49ﾱ14 23ﾱ9 15ﾱ5 52ﾱ25
Control 10 409ﾱ18 49ﾱ4 23ﾱ3 14ﾱ3 71ﾱ23
Mean ﾱ sd






Fig. 2. Ki67-positive cells (arrows) within the neointima at 14
days after injury of a control animal. (a) Rosuvastatin treatment
tended to reduce the proliferation index within the neointima
(number of Ki67-positive cells / total amount of cells). Howev-
er  at  day  14  no  significant  difference  could  be  detected
(p=0.058). (B) staining with immunofluorescence-labeled anti-
body against von Willebrand factor (secondary antibody alexa
594 in red) and _-smooth muscle actin in FItc (green) demon-
strated that reendotheliazation was not completed 14 days after
injury (arrow head) (_-smooth muscle actin in FItc, green). an
adventitial  artery  is  shown  as  a  positive  control  (arrow).  (c)
scale Bar = 100 ﾵm.
Fig.  1. neonintima  formation  of  the  common  carotid  artery
(hematoxylin / eosin staining) 14 days after balloon injury in a
control animal (a) and an animal treated with rosuvastatin. (B)
treatment with rosuvastatin leads to a reduction of neointima
size, as well as a reduction of neointima / media ratio. (c, d).
1 Preusch_Umbruchvorlage  11.11.10  17:27  Seite 464expression  in  the  rosuvastatin-treated  group,  com-
pared to controls. Proliferation after arterial injury is
commonly described as an early event which reaches a
maximum within the intimal layer between day four
and seven [27]. It is possible that the observed trend in
our study would reach statistical significance at an ear-
lier time point, as evaluated in the present study. other
studies  also  demonstrated  a  strong  association  be-
tween severe arterial injury with disruption of the in-
ternal  elastic  lamina  (IEl)  and  expression  of  Ki67.
thus, variability in severity of injury between different
studies  may  also  contribute  to  differences  in  time
course  of  proliferation  [28].  consistent  with  other
studies, proliferating cells are nearly exclusively located
in  the  luminal  surface.    Recently  published  data
demonstrated antiproliferative effects of Rosuvastatin
in an ex-vivo model of balloon injury via urokinase-
type plasminogen activator receptor (uPaR) [29]. Fur-
thermore,  data  acquired  by  our  group  and  others
showed inhibitory effects of statins on the activity of
the transcription factors Egr-1, nF-kappaB, and aP-1
[30, 31].
the  adjacent  cells  of  the  intact  vascular  wall  are
mainly responsible for wound repair after injury [3].
Recent data support the possibility that bone marrow-
derived  cells,  circulating  in  the  blood  stream  con-
tribute to neoangiogenesis and accelerated re-endothe-
lialisation leading to a reduction of neointima forma-
tion [32, 33]. Werner et al. (2002) demonstrated the
beneficial effects of endothelial progenitor cells in a
mouse model of carotid injury: rosuvastatin treatment
accelerated  re-endothelialisation  and  significantly  re-
duced neointimal formation [21]. However, it remains
unclear whether this is due to a direct effect of statin
therapy  or  due  to  a  statin-mediated  increase  in  the
number  of  circulating,  immature,  endothelial  cells
[34]. We observed a lack of re-endothelialisation at 14
days after injury that was not affected by statin treat-
ment.  differences  in  endothelial  recovery  between
studies can be explained by variable distances between
untraumatized endothelium and denuded areas, since
regeneration, at least in part, starts from the adjacent
non-injured endothelial layer [35]. It has been reported
that even as late as six weeks after injury, some areas
of the artery still remained without endothelium [36]. 
new data furthermore have demonstrated an asso-
ciation between statin treatment and the reduced risk
of  venous  thrombosis  which  implies  an  effect  of
HMG-coa  reductase  inhibition  and  the  coagulation
system [31, 32]. studies demonstrated a statin-induced
inhibition of the procoagulatory tissue factor and even
proposed tissue factor activity as a risk predictor of
restenosis after PcI and stent implantation [37, 38, 39,
40].
clinical studies have suggested that lipid-lowering
by  statins  protects  from  restenosis  after  coronary
stenting [41, 42]. It has been shown that rosuvastatin
significantly decreased ldl, cholesterol, and tri  glycer  -
ide  levels  and  that  high-dose  rosuvastatin  treatment
was more effective than similar doses of atorvastatin
in lowering direct ldl cholesterol [43]. In contrast,
our model, at the time of necropsy, showed no differ-
ences in total cholesterol, ldl, or Hdl between the
groups which also confirms a cholesterol-independent
effect on neointima formation in our in vivo-model.
the  lack  of  a  cholesterol-lowering  effect  of  statin
treatment in rodents has been investigated in several
studies and seems to be very common, even at higher
doses [44, 45]. the mechanisms how statin treatment
of  apoE-/-  mice  even  causes  an  increase  in  serum
cholesterol, as observed in some studies, is still unclear
[46]. one possible explanation is that continuous ad-
ministration of statins via chow even stimulates ex-
pression and/or activity of HMG-co a reductase in
the liver of treated mice.
In conclusion, our study demonstrates that rosuvas-
tatin inhibits neointima formation after balloon injury
and it supports the hypothesis that this effect is MMP-
9 independent.
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